Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes

Acta Diabetologica

Volumn 44, Issue 4, 2007, Pages 187-192

  Yilmaz, Hamiyet ^a   Gursoy, Alptekin ^a   Sahin, Mustafa ^a   Guvener Demirag, Nilgun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Acarbose; Combination; Insulin; Metformin; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; C REACTIVE PROTEIN; FIBRINOGEN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; ISOPHANE INSULIN; LIPID; METFORMIN; ROSIGLITAZONE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOATING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; EDEMA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ACARBOSE; AGE OF ONSET; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PATIENT SELECTION; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 36248935637     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-007-0004-9     Document Type: Article

References (25)

1. American Diabetes Association (2005) Standards of medical care in diabetes. Diabetes Care 28(Suppl 1):4-36
2. Bailey CJ (2005) Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7:675-691
3. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study. Implications for treatment. Circulation 85:37-45
4. Md Isa SH, Najihah I, Nazaimoon WM, Kamarudin NA, Umar NA, Mat NH, Khalid BA (2006) Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. Diabetes Res Clin Pract 72:48-52
5. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS (1997) Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537
6. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM (1996) The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19:1190-1193
7. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD (2002) Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25:542-549
8. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE (2001) Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029
9. Hsueh WA, Jackson S, Law RE (2001) Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24:392-397
10. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820
11. Sidhu JS, Cowan D, Kaski JC (2003) The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42:1757-1763
12. Sung BH, Izzo JL Jr, Dandona P, Wilson MF (1999) Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 34:83-88
13. Delorme S, Chiasson JL (2005) Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opin Pharmacol 5:184-189
14. Guvener N, Gedik O (1999) Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 36:93-97
15. Zimmerman BR (1992) Preventing long term complications. Implications for combination therapy with acarbose. Drugs 44(Suppl 3):54-60
16. Huang A, Raskin P (2005) Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Treat Endocrinol 4:205-220
17. Hermanns N, Burkert A, Haak T (2004) The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 112:310-314
18. Strowig SM, Aviles-Santa ML, Raskin P (2002) Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 25:1691-1698
19. Sangiorgio L, Attardo T, Condorelli L, Lunetta M (2000) Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin. Arch Gerontol Geriatr 31:27-34
20. Standl E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J (1999) Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab 1:215-220
21. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD (2002) Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25:2133-2140
22. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM (1999) A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 48:2414-2421
23. Wellington K (2005) Rosiglitazone/metformin. Drugs 65:1581-1592
24. Kobayashi J, Nagashima I, Hikita M, Bujo H, Takahashi K, Otabe M, Morisaki N, Saito Y (1999) Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 47:433-439
25. Schwartz S, Raskin P, Fonseca V, Graveline JF (1998) Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and exogenous insulin study group. N Engl J Med 338:861-866